GT201500035A - ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS - Google Patents
ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESSInfo
- Publication number
- GT201500035A GT201500035A GT201500035A GT201500035A GT201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A
- Authority
- GT
- Guatemala
- Prior art keywords
- microspheres
- pharmaceutical composition
- oral pharmaceutical
- elaboration process
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA ADMINISTRACIÓN ORAL EN FORMA DE MICROPARTÍCULAS, POR EJEMPLO MICROESFERAS O PELLETS, ASÍ COMO EL PROCESO PARA SU ELABORACIÓN. LA INVENCIÓN TAMBIÉN SE REFIERE A UNA COMPOSICIÓN QUE CONTIENE UN DIURÉTICO Y EL USO DE LA COMPOSICIÓN PARA EL TRATAMIENTO DE EDEMA, TRASTORNOS CARDIOVACULARES, HIPERTENSIÓN, DAÑO RENAL, DAÑO HEPÁTICO, ENTRE OTROS.THE PRESENT INVENTION REFERS TO A COMPOSITION FOR ORAL ADMINISTRATION IN THE FORM OF MICROPARTICLES, BY EXAMPLE MICROSPHERES OR PELLETS, AS WELL AS THE PROCESS FOR THEIR DEVELOPMENT. THE INVENTION ALSO REFERS TO A COMPOSITION CONTAINING A DIURETIC AND THE USE OF COMPOSITION FOR EDEMA TREATMENT, CARDIOVACULAR DISORDERS, HYPERTENSION, RENAL DAMAGE, HEART DAMAGE, BETWEEN OTHERS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012009583A MX351059B (en) | 2012-08-17 | 2012-08-17 | Oral pharmaceutical composition in the form of microspheres and preparation method. |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201500035A true GT201500035A (en) | 2017-10-24 |
Family
ID=50435594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201500035A GT201500035A (en) | 2012-08-17 | 2015-02-16 | ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS |
Country Status (8)
Country | Link |
---|---|
CL (1) | CL2015000375A1 (en) |
CO (1) | CO7310526A2 (en) |
CR (1) | CR20150077A (en) |
DO (1) | DOP2015000028A (en) |
GT (1) | GT201500035A (en) |
MX (1) | MX351059B (en) |
PE (1) | PE20150710A1 (en) |
WO (1) | WO2014027334A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2978859B1 (en) | 2013-03-27 | 2018-06-27 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
MX2017000582A (en) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent. |
CN104523710B (en) * | 2014-12-30 | 2018-05-25 | 石药集团欧意药业有限公司 | A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof |
KR101710441B1 (en) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | Tablet with improved stability and dissolution |
EP3582777A4 (en) | 2017-02-17 | 2020-12-23 | Unichem Laboratories Ltd | Pharmaceutical composition of apixaban |
CN106821996A (en) * | 2017-03-01 | 2017-06-13 | 华益药业科技(安徽)有限公司 | Enalapril maleate granule and preparation method thereof |
BR112020020941A2 (en) * | 2018-04-16 | 2021-03-02 | Bristol-Myers Squibb Company | apixaban formulations |
WO2021168043A1 (en) * | 2020-02-19 | 2021-08-26 | Nano Pharmasolutions, Inc. | Therapeutic agent nanoparticles and methods of preparation |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
CN113413364A (en) * | 2021-05-31 | 2021-09-21 | 辰欣药业股份有限公司 | Enoxaparin sodium injection and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007208998A1 (en) * | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
MXPA06010972A (en) * | 2006-09-25 | 2009-04-17 | World Trade Imp Export Wtie Ag | Process for stabilizing famotidine. |
WO2008045006A1 (en) * | 2006-10-11 | 2008-04-17 | Fako Ilaclari A. S. | Formulations of candesartan |
MX2007008440A (en) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Combined pharmaceutical composition. |
-
2012
- 2012-08-17 MX MX2012009583A patent/MX351059B/en active IP Right Grant
-
2013
- 2013-08-16 WO PCT/IB2013/056690 patent/WO2014027334A2/en active Application Filing
- 2013-08-16 PE PE2015000210A patent/PE20150710A1/en active IP Right Grant
-
2015
- 2015-02-13 CR CR20150077A patent/CR20150077A/en unknown
- 2015-02-16 GT GT201500035A patent/GT201500035A/en unknown
- 2015-02-16 DO DO2015000028A patent/DOP2015000028A/en unknown
- 2015-02-17 CL CL2015000375A patent/CL2015000375A1/en unknown
- 2015-03-04 CO CO15048826A patent/CO7310526A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014027334A3 (en) | 2014-04-10 |
DOP2015000028A (en) | 2015-03-15 |
PE20150710A1 (en) | 2015-05-28 |
CR20150077A (en) | 2015-05-13 |
MX351059B (en) | 2017-09-29 |
WO2014027334A2 (en) | 2014-02-20 |
MX2012009583A (en) | 2014-02-26 |
CL2015000375A1 (en) | 2015-07-10 |
CO7310526A2 (en) | 2015-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201500035A (en) | ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS | |
PE20150631A1 (en) | CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR | |
CL2014001158A1 (en) | Alkylated piperazine derivative compounds; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; kit and use in the treatment of immune disorders, cancer, cardiovascular diseases, inflammation, among others. | |
CL2015002164A1 (en) | Combined formulation of two antiviral compounds. | |
BR112015020389A2 (en) | carbazole compounds useful as bromodomain inhibitors | |
UY35590A (en) | NEW COMPOUNDS FOR CANCER TREATMENT | |
CL2014002757A1 (en) | Compounds derived from benzamide to inhibit the activity of abl1, abl2 and bcr-abl1, pharmaceutical composition; and use in the treatment of cancer. | |
CR20150326A (en) | AUTOTAXIN INHIBITORS | |
ECSP14026138A (en) | URACILOS REPLACED BICYCLICALLY AND USE OF THE SAME | |
CO6771417A2 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis | |
EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
MX2015016983A (en) | Nuclear transport modulators and uses thereof. | |
UY34918A (en) | New 5-aminotetrahydroquinolin-2-carboxylic acids and their use | |
UY33396A (en) | 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE | |
EA201591404A1 (en) | SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | |
CL2013002650A1 (en) | Tricyclic derivative compounds with activity on nuclear hormone receptors; pharmaceutical composition that includes them; intermediate compound repair process; and use in the treatment of AIDS, acute adrenal insufficiency, addison's disease, allergic rhinitis, Alzheimer's disease, among others. | |
CL2015001610A1 (en) | Compounds derived from pyrimido- [4,5-b] -quinoline-4,5 (3h, 10h) -diones to be used as a medicament for the treatment of a disease caused by a nonsense mutation; composition and pharmaceutical combination that includes them. | |
MX2016003823A (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma. | |
MX2016000294A (en) | Pharmaceutical composition for a sustained release of lanreotide. | |
CL2013003700A1 (en) | Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder. | |
GT201300304A (en) | 1-PIPERAZINO-3-PHENYL-INDANOS DEUTERATED FOR THE TREATMENT OF SCHIZOPHRENIA | |
UY34931A (en) | ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?. | |
BR112014031706A8 (en) | Oral pharmaceutical compositions, and oral pharmaceutical composition comprising itraconazole | |
CL2015001881A1 (en) | Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition. |